Skip to content
OpenCapital
Get started

Envoy Medical COCH Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF
Heartflow, Inc. Common StockHTFL
$15.41M-25.5%
Photronics logo
PhotronicsPLAB
$3.9M+43.5%
Starfighters Space, Inc. logo
Starfighters Space, Inc. FJET
$244.99K—
XTI Aerospace, Inc. logo
XTI Aerospace, Inc.XTIA
$756K-37.7%
Aptera Motors Corp. logo
Aptera Motors Corp. SEV
$10.84M-13.7%
NTH
NeOnc Technologies Holdings, Inc. Common StockNTHI
$1.23M—

Other financials

Income statement

See full
Revenue$39.0K-15.2%
Gross profit-$274.0K-52.2%
Operating income-$6.0M-16.7%
Net income-$4.4M+12.9%
EPS (diluted)-$0.08+72.4%

Balance sheet

See full
Cash & equivalents$25.3M+376%
Total debt$919.0K-2.8%
Total equity$10.2M+142%
Total assets$29.8M+187%

Cash flow

See full
Operating cash flow-$6.1M-62.7%
CapEx$172.0K—
Free cash flow-$5.9M-28.5%

Valuation

See full
Market cap$61M+83.5%
P/S260.7×+111×

Profitability

See full
Gross margin-310.7%+31.6pp
Operating margin-9,881.2%+805pp
Net margin-9,875.6%+771pp
FCF margin-7,626.6%-652pp

Returns & leverage

See full
Return on equity328.7%—
Debt / equity0.1×—
Current ratio2.3×+1.2×

Where this comes from

Reported directly by Envoy Medical in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: Envoy Medical’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Envoy Medical's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Envoy Medical's indefinite-lived research and development assets?
Envoy Medical (COCH) reported indefinite-lived research and development assets of $2.06M in Q4 2025.
What is the long-term trend for Envoy Medical's indefinite-lived research and development assets?
Over 3 years (2022 to 2025), Envoy Medical's indefinite-lived research and development assets has grown at a 0.3% compound annual growth rate (CAGR), from $2.04M to $2.06M.
What does indefinite-lived research and development assets mean?
The value of acquired research and development projects that have not yet reached technological feasibility and thus are not subject to amortization. This metric highlights the company's investment in long-term innovation and future growth potential.